Hereditary Transthyretin Amyloidosis Market Research 2025: In-Depth Analysis of Size, Share & Forecast

30 Apr, 2025

The Hereditary Transthyretin Amyloidosis Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.

What are the Historical Growth Trends in the Hereditary Transthyretin Amyloidosis Market?

The market size of the hereditary transthyretin amyloidosis sector has seen robust growth recently. The market is projected to expand from a value of $1.36 billion in 2024 to $1.50 billion in 2025, with a compound annual growth rate (CAGR) of 9.7%.

What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Hereditary Transthyretin Amyloidosis Industry?

The Hereditary Transthyretin Amyloidosis Global Market is projected to reach $2.14 billion in 2029, experiencing a compound annual growth rate (CAGR) of 9.4%.

Download Your Free Sample of the 2025 Hereditary Transthyretin Amyloidosis Market Report and Uncover Key Trends Now!

What are the Key Growth Drivers Fueling the Hereditary Transthyretin Amyloidosis Market?

The key drivers in the hereditary transthyretin amyloidosis market are:

• The increasing geriatric population
• Rising incidence of hereditary transthyretin amyloidosis
• The development of new drugs for treatment
• Advancements in genetic testing capabilities

Global Market Segmentation: Identifying Major Hereditary Transthyretin Amyloidosis Industry Segments

The hereditary transthyretin amyloidosis market covered in this report is segmented –
1) By Type: Oral, Subcutaneous Injection, Other Types
2) By Drug Class: RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) By Application: Hospital, Clinic, Other Applications Subsegments:
1) By Oral: Tafamidis, Diflunisal, Experimental Oral Therapies
2) By Subcutaneous Injection: Patisiran, Inotersen, Vutrisiran
3) By Other Types: Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies

Pre-order the 2025 Hereditary Transthyretin Amyloidosis Global Market Report for Fast Delivery & Comprehensive Insights!

What are the emerging Trends Shaping the Future of the Hereditary Transthyretin Amyloidosis Market?

The key trends in the hereditary transthyretin amyloidosis market are:

• The future of the market is being shaped by the development of advanced treatment products.
• Improvements in diagnostic techniques are playing a key role in market trends.
• The market is being influenced by advancements in drug development.
• The demand for effective therapies is a significant emerging trend.

Who Are the Top Competitors & Leading Players in the Hereditary Transthyretin Amyloidosis Market?

Major players in the hereditary transthyretin amyloidosis market are:

• Pfizer Inc.
• AbbVie Inc.
• Sanofi S.A.
• AstraZeneca plc
• Novo Nordisk
• Regeneron Pharmaceuticals Inc.
• Alexion Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• PTC Therapeutics Inc.
• Ionis Pharmaceuticals Inc.
• BridgeBio Pharma Inc.
• Akcea Therapeutics
• Prothena Corporation plc
• Intellia Therapeutics Inc.
• YoITech Therapeutics
• Corino Therapeutics Inc.
• Attralus Inc.
• BSIM Therapeutics SA
• Eidos Therapeutics
• Autotac Bio Inc.

Regional Dominance: Which Area Leads the Global Template Market?

North America was the largest region in the hereditary transthyretin amyloidosis market in 2024